Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
| Revenue (TTM) | $9.29M |
| Gross Profit (TTM) | $9.29M |
| EBITDA | $-21.95M |
| Operating Margin | -1024.00% |
| Return on Equity | -28.50% |
| Return on Assets | -14.00% |
| Revenue/Share (TTM) | $0.18 |
| Book Value | $1.33 |
| Price-to-Book | 2.21 |
| Price-to-Sales (TTM) | 14.89 |
| EV/Revenue | 8.21 |
| EV/EBITDA | 1.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7333.00% |
| Shares Outstanding | $67.14M |
| Float | $44.83M |
| % Insiders | 11.40% |
| % Institutions | 36.04% |
Volatility is currently expanding
Adagene NASDAQ: ADAG Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development milestones during a discussion focused on its T-cell engager, or TCE, portfolio.
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C.
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China's National Medical Products Administration (NMPA) has approved the company's investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T cell engager built on Adagene's proprietary SAFEbody® precision masking technology.
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026 Format: 1x1 Meetings Date/Time: September 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026 Format: Fireside Chat and 1x1 Meetings Fireside Chat Date/Time: September 15, 2026, 10:45–11:20 AM (Eastern Time) H.C.
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ADAG and any ticker you trade — then tracks every position and per-strategy win rate.
